{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:36:32Z","timestamp":1786984592492,"version":"build-2736575974"},"reference-count":279,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T00:00:00Z","timestamp":1757030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.apsb.2025.09.008","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:50:50Z","timestamp":1757573450000},"page":"5493-5514","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Antisense molecules: A promising new therapy for atopic dermatitis"],"prefix":"10.1016","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5658-1340","authenticated-orcid":false,"given":"Jiayi","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhirong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2025.09.008_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1186\/s13052-021-01157-7","article-title":"Association of exposure to hydrocarbon air pollution with the incidence of atopic dermatitis in children","volume":"47","author":"Wang","year":"2021","journal-title":"Ital J Pediatr"},{"key":"10.1016\/j.apsb.2025.09.008_bib2","series-title":"Dermatology","author":"Amagai","year":"2018"},{"key":"10.1016\/j.apsb.2025.09.008_bib3","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1111\/j.1468-3083.2012.04578.x","article-title":"Relationship between itch and psychological status of patients with atopic dermatitis","volume":"27","author":"Chrostowska-Plak","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.apsb.2025.09.008_bib4","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.anai.2018.07.042","article-title":"Association of atopic dermatitis with allergic, autoimmune, and cardiovascular comorbidities in US adults","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib7","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: beyond allergic disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib8","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/j.jaci.2013.07.008","article-title":"Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation","volume":"132","author":"Schmitt","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib9","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/all.12184","article-title":"Immunology of atopic eczema: overcoming the Th1\/Th2 paradigm","volume":"68","author":"Eyerich","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.apsb.2025.09.008_bib10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaad.2021.10.038","article-title":"Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: real-world evidence","volume":"86","author":"Paller","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib11","first-page":"269","article-title":"Epidemiology of atopic dermatitis and atopic march in children","volume":"30","author":"Spergel","year":"2010","journal-title":"Immunol Allergy Clin"},{"key":"10.1016\/j.apsb.2025.09.008_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.jid.2016.07.012","article-title":"The burden of atopic dermatitis: summary of a report for the National Eczema Association","volume":"137","author":"Drucker","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib13","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.09.008_bib14","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/s41423-023-00992-4","article-title":"The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment","volume":"20","author":"Facheris","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib15","unstructured":"European Medicines Agency. Dupixent : EPAR - Product Information. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/dupixent. (Accessed 30 April 2025)."},{"key":"10.1016\/j.apsb.2025.09.008_bib16","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0140-6736(24)01203-0","article-title":"Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials","volume":"404","author":"Silverberg","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.09.008_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10787-024-01614-9","article-title":"Pharmaceutical aspects of JAK inhibitors: a comparative review","volume":"33","author":"Jinesh","year":"2025","journal-title":"Inflammopharmacology"},{"key":"10.1016\/j.apsb.2025.09.008_bib18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s12016-022-08934-0","article-title":"Dupilumab-associated adverse events during treatment of allergic diseases","volume":"62","author":"Kychygina","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib19","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib20","doi-asserted-by":"crossref","first-page":"3802","DOI":"10.1016\/j.apsb.2024.05.008","article-title":"Current status and trends in small nucleic acid drug development: leading the future","volume":"14","author":"Miao","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.09.008_bib21","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1016\/j.jaci.2015.12.1344","article-title":"Antisense molecules: a new class of drugs","volume":"137","author":"Potaczek","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib22","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.jaci.2017.08.034","article-title":"MicroRNA","volume":"141","author":"Lu","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib23","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2013.04.039","article-title":"Diagnostic, functional, and therapeutic roles of microRNA in allergic diseases","volume":"132","author":"Lu","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib24","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cmet.2018.03.004","article-title":"RNA-targeted therapeutics","volume":"27","author":"Crooke","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.apsb.2025.09.008_bib25","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2165\/00003495-199957030-00010","article-title":"Fomivirsen","volume":"57","author":"Perry","year":"1999","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib26","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s40265-013-0042-2","article-title":"Mipomersen sodium: first global approval","volume":"73","author":"Hair","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib27","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-017-0711-7","article-title":"Nusinersen: first global approval","volume":"77","author":"Hoy","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: first global approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib29","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1007\/s40265-018-0968-5","article-title":"Inotersen: first global approval","volume":"78","author":"Keam","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: first approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib31","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s40265-019-01168-z","article-title":"Volanesorsen: first global approval","volume":"79","author":"Paik","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib32","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: first approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib33","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: first approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib34","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s40265-023-01904-6","article-title":"Tofersen: first approval","volume":"83","author":"Blair","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40265-024-02008-5","article-title":"Eplontersen: first approval","volume":"84","author":"Nie","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib36","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: first approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib37","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40265-020-01463-0","article-title":"Lumasiran: first approval","volume":"81","author":"Scott","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib38","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s40265-021-01473-6","article-title":"Inclisiran: first approval","volume":"81","author":"Lamb","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib39","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1007\/s40265-022-01765-5","article-title":"Vutrisiran: first approval","volume":"82","author":"Keam","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib40","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1007\/s40265-023-01976-4","article-title":"Nedosiran: first approval","volume":"83","author":"Syed","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib41","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s40265-018-0983-6","article-title":"Patisiran: first global approval","volume":"78","author":"Hoy","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib42","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1038\/s41467-022-34216-6","article-title":"Genome-wide association and multi-trait analyses characterize the common genetic architecture of heart failure","volume":"13","author":"Levin","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.008_bib43","article-title":"Nucleic acid therapeutics: past, present, and future","volume":"36","author":"Naeem","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2025.09.008_bib44","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1056\/NEJMoa2210027","article-title":"Efficacy and safety of bepirovirsen in chronic hepatitis B infection","volume":"387","author":"Yuen","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.apsb.2025.09.008_bib46","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2025.09.008_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114196","article-title":"Antisense drug discovery and development technology considered in a pharmacological context","volume":"189","author":"Crooke","year":"2021","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.apsb.2025.09.008_bib48","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nrd3625","article-title":"RNA therapeutics: beyond RNA interference and antisense oligonucleotides","volume":"11","author":"Kole","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.09.008_bib49","doi-asserted-by":"crossref","first-page":"48","DOI":"10.59566\/IJBS.2017.13048","article-title":"Molecular mechanisms and biological functions of siRNA","volume":"13","author":"Dana","year":"2017","journal-title":"Int J Biomed Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib50","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.cell.2009.01.002","article-title":"MicroRNAs: target recognition and regulatory functions","volume":"136","author":"Bartel","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.09.008_bib51","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.jaci.2013.04.011","article-title":"MicroRNAs: essential players in the regulation of inflammation","volume":"132","author":"Rebane","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib52","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0167-7799(94)90138-4","article-title":"Inventing and improving ribozyme function: rational design versus iterative selection methods","volume":"12","author":"Breaker","year":"1994","journal-title":"Trends Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib53","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2022.10.011","article-title":"Oleic acid-based vesicular nanocarriers for topical delivery of the natural drug thymoquinone: improvement of anti-inflammatory activity","volume":"352","author":"Bruno","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.09.008_bib54","series-title":"Pharmaceutics: the science of dosage form design","author":"Aulton","year":"2002"},{"key":"10.1016\/j.apsb.2025.09.008_bib55","doi-asserted-by":"crossref","first-page":"6484","DOI":"10.3390\/ijms21186484","article-title":"Genetic and epigenetic aspects of atopic dermatitis","volume":"21","author":"Nedoszytko","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib56","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/ng1767","article-title":"Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis","volume":"38","author":"Palmer","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.apsb.2025.09.008_bib57","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/ijms23105318","article-title":"Revisiting the roles of filaggrin in atopic dermatitis","volume":"23","author":"Moosbrugger-Martinz","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.09.015","article-title":"Effect of filaggrin breakdown products on growth of and protein expression by Staphylococcus aureus","volume":"126","author":"Miajlovic","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib59","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.jaci.2014.06.014","article-title":"Causes of epidermal filaggrin reduction and their role in the pathogenesis of atopic dermatitis","volume":"134","author":"Thyssen","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib60","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1038\/jid.2008.29","article-title":"Loss-of-function mutations in the filaggrin gene lead to reduced level of natural moisturizing factor in the stratum corneum","volume":"128","author":"Kezic","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib61","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/jid.2008.413","article-title":"Eczema genetics: current state of knowledge and future goals","volume":"129","author":"Brown","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.10.018","article-title":"Tight junction defects in patients with atopic dermatitis","volume":"127","author":"De Benedetto","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib63","doi-asserted-by":"crossref","first-page":"6172","DOI":"10.1038\/s41467-023-41180-2","article-title":"European and multi-ancestry genome-wide association meta-analysis of atopic dermatitis highlights importance of systemic immune regulation","volume":"14","author":"Budu-Aggrey","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.008_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn7774","article-title":"ROR\u03b3t expression in mature TH17 cells safeguards their lineage specification by inhibiting conversion to TH2 cells","volume":"8","author":"Chi","year":"2022","journal-title":"Sci Adv"},{"key":"10.1016\/j.apsb.2025.09.008_bib65","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2500\/aap.2015.36.3808","article-title":"Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema\/dermatitis syndrome (AEDS): association with clinical severity and phenotype","volume":"36","author":"Leonardi","year":"2015","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.apsb.2025.09.008_bib66","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/all.12633","article-title":"Mutual upregulation of endothelin-1 and IL-25 in atopic dermatitis","volume":"70","author":"Aktar","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.apsb.2025.09.008_bib67","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1038\/jid.2008.111","article-title":"Possible pathogenic role of Th17 cells for atopic dermatitis","volume":"128","author":"Koga","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib68","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/jdv.16126","article-title":"IL-17C amplifies epithelial inflammation in human psoriasis and atopic eczema","volume":"34","author":"Lauffer","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.apsb.2025.09.008_bib69","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/j.jaad.2010.02.049","article-title":"Markedly elevated serum levels of calcium-binding S100A8\/A9 proteins in psoriatic arthritis are due to activated monocytes\/macrophages","volume":"64","author":"Aochi","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib70","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1189\/jlb.1008647","article-title":"The endogenous Toll-like receptor 4 agonist S100A8\/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer","volume":"86","author":"Ehrchen","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.apsb.2025.09.008_bib71","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1139\/Y09-054","article-title":"S100A8\/A9: a mediator of severe asthma pathogenesis and morbidity?","volume":"87","author":"Halayko","year":"2009","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.apsb.2025.09.008_bib72","first-page":"359","article-title":"Inside out or outside in: does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis?","volume":"96","author":"Silverberg","year":"2015","journal-title":"Cutis"},{"key":"10.1016\/j.apsb.2025.09.008_bib73","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/ni734","article-title":"Mutation of Tec family kinases alters T helper cell differentiation","volume":"2","author":"Schaeffer","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib74","doi-asserted-by":"crossref","first-page":"6435","DOI":"10.4049\/jimmunol.163.12.6435","article-title":"Regulated association between the tyrosine kinase Emt\/Itk\/Tsk and phospholipase-C gamma 1 in human T lymphocytes","volume":"163","author":"Perez-Villar","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib75","doi-asserted-by":"crossref","first-page":"6375","DOI":"10.4049\/jimmunol.161.11.6375","article-title":"Costimulation through CD86 is involved in airway antigen-presenting cell and T cell responses to allergen in atopic asthmatics","volume":"161","author":"Larch\u00e9","year":"1998","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib76","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1084\/jem.185.9.1671","article-title":"Costimulation through B7-2 (CD86) is required for the induction of a lung mucosal T helper cell 2 (TH2) immune response and altered airway responsiveness","volume":"185","author":"Tsuyuki","year":"1997","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib77","doi-asserted-by":"crossref","first-page":"3741","DOI":"10.3390\/jcm9113741","article-title":"Regulation of skin barrier function via competition between AHR axis versus IL-13\/IL-4\u2012JAK\u2012STAT6\/STAT3 axis: pathogenic and therapeutic implications in atopic dermatitis","volume":"9","author":"Furue","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib78","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK\u2012STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib79","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib80","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.3390\/ijms19103086","article-title":"New cytokines in the pathogenesis of atopic dermatitis-new therapeutic targets","volume":"19","author":"Klonowska","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib81","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imr.12558","article-title":"IL-25 in allergic inflammation","volume":"278","author":"Xu","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2025.09.008_bib82","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/intimm\/11.1.81","article-title":"Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine","volume":"11","author":"Imai","year":"1999","journal-title":"Int Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib83","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1016\/S0002-9440(10)64077-1","article-title":"Macrophage-derived chemokine (MDC\/CCL22) and CCR4 are involved in the formation of T lymphocyte-dendritic cell clusters in human inflamed skin and secondary lymphoid tissue","volume":"158","author":"Katou","year":"2001","journal-title":"Am J Pathol"},{"key":"10.1016\/j.apsb.2025.09.008_bib84","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1399-3038.2007.00692.x","article-title":"Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis","volume":"19","author":"Nakazato","year":"2008","journal-title":"Pediatr Allergy Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib85","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/35100529","article-title":"Toll-like receptors and innate immunity","volume":"1","author":"Medzhitov","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/BJ20090272","article-title":"Pathogen recognition in the innate immune response","volume":"420","author":"Kumar","year":"2009","journal-title":"Biochem J"},{"key":"10.1016\/j.apsb.2025.09.008_bib87","doi-asserted-by":"crossref","first-page":"4130","DOI":"10.3390\/ijms22084130","article-title":"Molecular mechanisms of atopic dermatitis pathogenesis","volume":"22","author":"Sroka-Tomaszewska","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib88","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.3390\/ijms22041507","article-title":"Immunological roles of NLR in allergic diseases and its underlying mechanisms","volume":"22","author":"Tsang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib89","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1056\/NEJMoa021481","article-title":"Endogenous antimicrobial peptides and skin infections in atopic dermatitis","volume":"347","author":"Ong","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib90","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jaci.2014.02.017","article-title":"Toll-like receptor 2 ligands promote chronic atopic dermatitis through IL-4-mediated suppression of IL-10","volume":"134","author":"Kaesler","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib91","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/jid.2013.291","article-title":"Nonpathogenic bacteria alleviating atopic dermatitis inflammation induce IL-10-producing dendritic cells and regulatory Tr1 cells","volume":"134","author":"Volz","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib92","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1111\/j.1398-9995.2011.02571.x","article-title":"Atopic dermatitis\u2014from new pathophysiologic insights to individualized therapy","volume":"66","author":"Novak","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.apsb.2025.09.008_bib93","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jaip.2023.02.005","article-title":"Targeting skin barrier function in atopic dermatitis","volume":"11","author":"van den Bogaard","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.apsb.2025.09.008_bib94","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1194\/jlr.P030338","article-title":"Increase in short-chain ceramides correlates with an altered lipid organization and decreased barrier function in atopic eczema patients","volume":"53","author":"Janssens","year":"2012","journal-title":"J Lipid Res"},{"key":"10.1016\/j.apsb.2025.09.008_bib95","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/sj.jid.5700288","article-title":"Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome","volume":"126","author":"Hachem","year":"2006","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib96","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1080\/25785826.2019.1628467","article-title":"Future trends in the treatment of atopic dermatitis","volume":"42","author":"Igawa","year":"2019","journal-title":"Immunol Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib97","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms13946","article-title":"The transcription factor EPAS1 links DOCK8 deficiency to atopic skin inflammation via IL-31 induction","volume":"8","author":"Yamamura","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.008_bib98","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1136\/bmj.311.7015.1241","article-title":"Atopic eczema","volume":"311","author":"Williams","year":"1995","journal-title":"BMJ"},{"key":"10.1016\/j.apsb.2025.09.008_bib99","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-981-15-3449-2_4","article-title":"The role of genetics, the environment, and epigenetics in atopic dermatitis","volume":"1253","author":"Mu","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.apsb.2025.09.008_bib100","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2010.05.045","article-title":"MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4","volume":"126","author":"Sonkoly","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib101","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0046082","article-title":"MicroRNA-155 modulates Treg and Th17 cells differentiation and Th17 cell function by targeting SOCS1","volume":"7","author":"Yao","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.09.008_bib102","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s004180000143","article-title":"Disruption of epithelial tight junctions is prevented by cyclic nucleotide-dependent protein kinase inhibitors","volume":"113","author":"Klingler","year":"2000","journal-title":"Histochem Cell Biol"},{"key":"10.1016\/j.apsb.2025.09.008_bib103","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s11010-016-2696-z","article-title":"MicroRNA-143 inhibits IL-13-induced dysregulation of the epidermal barrier-related proteins in skin keratinocytes via targeting to IL-13R\u03b11","volume":"416","author":"Zeng","year":"2016","journal-title":"Mol Cell Biochem"},{"key":"10.1016\/j.apsb.2025.09.008_bib104","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2020.615850","article-title":"Exosomes of human umbilical cord MSCs protect against hypoxia\/reoxygenation-induced pyroptosis of cardiomyocytes via the miRNA-100-5p\/FOXO3\/NLRP3 pathway","volume":"8","author":"Liang","year":"2021","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib105","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1038\/jid.2014.89","article-title":"MiR-146a negatively regulates TLR2-induced inflammatory responses in keratinocytes","volume":"134","author":"Meisgen","year":"2014","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib106","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2014.05.022","article-title":"MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes","volume":"134","author":"Rebane","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib107","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.cellimm.2017.08.003","article-title":"MicroRNA-124 alleviates chronic skin inflammation in atopic eczema via suppressing innate immune responses in keratinocytes","volume":"319","author":"Yang","year":"2017","journal-title":"Cell Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib108","doi-asserted-by":"crossref","first-page":"8904","DOI":"10.1038\/s41598-023-34418-y","article-title":"Exosomes with overexpressed miR 147a suppress angiogenesis and infammatory injury in an experimental model of atopic dermatitis","volume":"13","author":"Shi","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2025.09.008_bib109","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1089\/ars.2011.4381","article-title":"Nutrition, epigenetics, and metabolic syndrome","volume":"17","author":"Wang","year":"2012","journal-title":"Antioxidants Redox Signal"},{"key":"10.1016\/j.apsb.2025.09.008_bib110","series-title":"Progress in molecular biology and translational science","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/B978-0-12-800977-2.00007-3","article-title":"The intergenerational effects of early adversity","author":"Galler","year":"2014"},{"key":"10.1016\/j.apsb.2025.09.008_bib111","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jaci.2013.06.036","article-title":"Maternal and cord blood miR-223 expression associates with prenatal tobacco smoke exposure and low regulatory T-cell numbers","volume":"133","author":"Herberth","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib112","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/genes11040442","article-title":"Genetics and epigenetics of atopic dermatitis: an updated systematic review","volume":"11","author":"Martin","year":"2020","journal-title":"Genes"},{"key":"10.1016\/j.apsb.2025.09.008_bib113","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/jdv.15973","article-title":"Neuroimmune interactions in chronic itch of atopic dermatitis","volume":"34","author":"Yosipovitch","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.apsb.2025.09.008_bib114","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.09.008_bib115","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2025.09.008_bib116","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s12016-015-8488-5","article-title":"Mediators of chronic pruritus in atopic dermatitis: getting the itch out?","volume":"51","author":"Mollanazar","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib117","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1001\/archderm.139.11.1479","article-title":"Modern aspects of cutaneous neurogenic inflammation","volume":"139","author":"Steinhoff","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib118","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S1474-4422(18)30217-5","article-title":"Clinical presentation, management, and pathophysiology of neuropathic itch","volume":"17","author":"Steinhoff","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.apsb.2025.09.008_bib119","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1126\/science.1233765","article-title":"The cells and circuitry for itch responses in mice","volume":"340","author":"Mishra","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.09.008_bib120","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1101\/gr.131029.111","article-title":"Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis","volume":"22","author":"Kong","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.apsb.2025.09.008_bib121","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2133.1974.tb06447.x","article-title":"Staphylococcus aureus in the lesions of atopic dermatitis","volume":"90","author":"Leyden","year":"1974","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib122","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nature12655","article-title":"Staphylococcus \u03b4-toxin induces allergic skin disease by activating mast cells","volume":"503","author":"Nakamura","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.09.008_bib123","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2010.03.044","article-title":"Superantigens in dermatology","volume":"64","author":"Macias","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib124","article-title":"Angiogenesis in chronic inflammatory skin disorders","volume":"22","author":"Lee","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib125","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abj0324","article-title":"NF-\u03baB perturbation reveals unique immunomodulatory functions in Prx1+ fibroblasts that promote development of atopic dermatitis","volume":"14","author":"Ko","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib126","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1126\/science.1093889","article-title":"Modulation of Th1 activation and inflammation by the NF-kappaB repressor Foxj1","volume":"303","author":"Lin","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.09.008_bib127","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1016\/j.jaci.2017.01.011","article-title":"The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies","volume":"139","author":"Brunner","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib128","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2011.05.016","article-title":"Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets","volume":"128","author":"Fujita","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib129","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.jaci.2012.02.020","article-title":"Mechanisms of IFN-\u03b3-induced apoptosis of human skin keratinocytes in patients with atopic dermatitis","volume":"129","author":"Rebane","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib130","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1471-4906(00)01812-3","article-title":"RANTES: a versatile and controversial chemokine","volume":"22","author":"Appay","year":"2001","journal-title":"Trends Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib131","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ni.1984","article-title":"Mouse CCL8, a CCR8 agonist, promotes atopic dermatitis by recruiting IL-5+ TH2 cells","volume":"12","author":"Islam","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib132","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.4049\/jimmunol.1401862","article-title":"NFAT1 and JunB cooperatively regulate IL-31 gene expression in CD4+ T cells in health and disease","volume":"194","author":"Hwang","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib133","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/bjd\/ljad078","article-title":"TMEM232 promotes the inflammatory response in atopic dermatitis via the nuclear factor-\u03baB and signal transducer and activator of transcription 3 signalling pathways","volume":"189","author":"Han","year":"2023","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib134","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1172\/JCI8204","article-title":"Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation","volume":"104","author":"Ray","year":"1999","journal-title":"J Clin Investig"},{"key":"10.1016\/j.apsb.2025.09.008_bib135","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1084\/jem.193.11.1247","article-title":"Treatment of allergic airway inflammation and hyperresponsiveness by antisense-induced local blockade of GATA-3 expression","volume":"193","author":"Finotto","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib136","doi-asserted-by":"crossref","first-page":"2956","DOI":"10.4049\/jimmunol.170.6.2956","article-title":"Protein kinase A regulates GATA-3-dependent activation of IL-5 gene expression in Th2 cells","volume":"170","author":"Klein-Hessling","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib137","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/09629359891126","article-title":"Topical glucocorticoids and the skin\u2014mechanisms of action: an update","volume":"7","author":"Ahluwalia","year":"1998","journal-title":"Mediat Inflamm"},{"key":"10.1016\/j.apsb.2025.09.008_bib138","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s40272-013-0013-9","article-title":"Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations","volume":"15","author":"Carr","year":"2013","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.apsb.2025.09.008_bib139","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/S1367-5931(99)80068-4","article-title":"Phosphodiesterase 4 inhibitors as novel anti-inflammatory agents","volume":"3","author":"Doherty","year":"1999","journal-title":"Curr Opin Chem Biol"},{"key":"10.1016\/j.apsb.2025.09.008_bib140","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1001\/jamadermatol.2019.0008","article-title":"Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis","volume":"155","author":"Yang","year":"2019","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib141","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1471-2407-6-7","article-title":"The carcinogenic potential of tacrolimus ointment beyond immune suppression: a hypothesis creating case report","volume":"6","author":"Becker","year":"2006","journal-title":"BMC Cancer"},{"key":"10.1016\/j.apsb.2025.09.008_bib142","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0163-7258(02)00297-8","article-title":"Mechanisms involved in the side effects of glucocorticoids","volume":"96","author":"Sch\u00e4cke","year":"2002","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1365-2133.2006.07343.x","article-title":"Update on the use of ciclosporin in immune-mediated dermatoses","volume":"155","author":"Griffiths","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib144","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1111\/j.1365-2133.2007.07879.x","article-title":"Dose-related reduction in allergen-specific T cells associates with clinical response of atopic dermatitis to methotrexate","volume":"156","author":"Bateman","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib145","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib146","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0140-6736(22)01199-0","article-title":"Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial","volume":"400","author":"Reich","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2025.09.008_bib147","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1606490","article-title":"Anti-interleukin-31 receptor A antibody for atopic dermatitis","volume":"376","author":"Ruzicka","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib148","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107830","article-title":"Advances in the pathophysiology of atopic dermatitis revealed by novel therapeutics and clinical trials","volume":"224","author":"Yang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib149","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jaci.2010.11.030","article-title":"Mechanisms of allergen-specific immunotherapy","volume":"127","author":"Ca","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib150","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2012.08.004","article-title":"Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis","volume":"130","author":"Novak","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib151","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1080\/21691401.2019.1640709","article-title":"Sublingual immunotherapy of atopic dermatitis in mite-sensitized patients: a multi-centre, randomized, double-blind, placebo-controlled study","volume":"47","author":"Liu","year":"2019","journal-title":"Artif Cells, Nanomed Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib152","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/ijd.12302","article-title":"Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis","volume":"53","author":"Qin","year":"2014","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib153","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1038\/s41422-021-00491-z","article-title":"In vivo self-assembled small RNAs as a new generation of RNAi therapeutics","volume":"31","author":"Fu","year":"2021","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2025.09.008_bib154","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.addr.2007.03.009","article-title":"Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications","volume":"59","author":"Kumar","year":"2007","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.09.008_bib155","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1261\/rna.25706","article-title":"Widespread siRNA \"off-target\" transcript silencing mediated by seed region sequence complementarity","volume":"12","author":"Jackson","year":"2006","journal-title":"RNA"},{"key":"10.1016\/j.apsb.2025.09.008_bib156","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nmeth854","article-title":"3\u2032 UTR seed matches, but not overall identity, are associated with RNAi off-targets","volume":"3","author":"Birmingham","year":"2006","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2025.09.008_bib157","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1089\/hum.2007.179","article-title":"Overcoming the innate immune response to small interfering RNA","volume":"19","author":"Judge","year":"2008","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib158","doi-asserted-by":"crossref","first-page":"e5","DOI":"10.1038\/mtna.2011.4","article-title":"siRNA-optimized modifications for enhanced in vivo activity","volume":"1","author":"Kenski","year":"2012","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2025.09.008_bib159","first-page":"647","article-title":"In vitro and in vivo pharmacologic activities of antisense oligonucleotides","volume":"6","author":"Mirabelli","year":"1991","journal-title":"Anti Cancer Drug Des"},{"key":"10.1016\/j.apsb.2025.09.008_bib160","series-title":"Antisense research and applications","author":"Crooke","year":"1993"},{"key":"10.1016\/j.apsb.2025.09.008_bib161","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41587-019-0106-2","article-title":"Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index","volume":"37","author":"Shen","year":"2019","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib162","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/104303404322886110","article-title":"Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease","volume":"15","author":"Hanai","year":"2004","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib163","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0022-3565(24)35316-9","article-title":"Enhanced anti-inflammatory activity of a liposomal intercellular adhesion molecule-1 antisense oligodeoxynucleotide in an acute model of contact hypersensitivity","volume":"292","author":"Klimuk","year":"2000","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2025.09.008_bib164","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.gt.3301724","article-title":"Prevention and regression of atopic dermatitis by ointment containing NF-\u03baB decoy oligodeoxynucleotides in NC\/Nga atopic mouse model","volume":"9","author":"Nakamura","year":"2002","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib165","first-page":"101","article-title":"A nucleic acid-based medications for severe atopic dermatitis-clinical trial of NF-\u03baB decoy ointment","volume":"210","author":"Tamai","year":"2004","journal-title":"Igaku no Ayumi"},{"key":"10.1016\/j.apsb.2025.09.008_bib166","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1124\/jpet.111.180042","article-title":"Therapeutic effects on atopic dermatitis by anti-RelA short interfering RNA combined with functional peptides Tat and AT1002","volume":"338","author":"Uchida","year":"2011","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2025.09.008_bib167","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1248\/cpb.59.196","article-title":"Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002","volume":"59","author":"Uchida","year":"2011","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"10.1016\/j.apsb.2025.09.008_bib168","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.ijpharm.2015.05.003","article-title":"Functional peptide nanocarriers for delivery of novel anti-RelA RNA interference agents as a topical treatment of atopic dermatitis","volume":"489","author":"Kanazawa","year":"2015","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.09.008_bib169","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/molecules21101279","article-title":"Development of an innovative intradermal siRNA delivery system using a combination of a functional stearylated cytoplasm-responsive peptide and a tight junction-opening peptide","volume":"21","author":"Ibaraki","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.apsb.2025.09.008_bib170","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1038\/sj.gt.3302341","article-title":"In vivo transfection of a cis element 'decoy' against signal transducers and activators of transcription 6 (STAT6)-binding site ameliorates IgE-mediated late-phase reaction in an atopic dermatitis mouse model","volume":"11","author":"Yokozeki","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib171","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1365-2133.2009.09070.x","article-title":"A therapeutic effect of STAT6 decoy oligodeoxynucleotide ointment in atopic dermatitis: a pilot study in adults","volume":"160","author":"Igawa","year":"2009","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib172","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1398-9995.2010.02440.x","article-title":"Gene silencing of STAT6 with siRNA ameliorates contact hypersensitivity and allergic rhinitis","volume":"66","author":"Hosoya","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.apsb.2025.09.008_bib173","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/sj.gt.3302171","article-title":"Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC\/Nga mice","volume":"11","author":"Sakamoto","year":"2004","journal-title":"Gene Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib174","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/jgm.1268","article-title":"Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis","volume":"11","author":"Kim","year":"2009","journal-title":"J Gene Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib175","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/mt.2008.91","article-title":"Topical application of cream-emulsified CD86 siRNA ameliorates allergic skin disease by targeting cutaneous dendritic cells","volume":"16","author":"Ritprajak","year":"2008","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib176","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0625.2010.01198.x","article-title":"Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases","volume":"20","author":"von Bonin","year":"2011","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib177","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3858\/emm.2011.43.2.008","article-title":"Therapeutic effects of recombinant Salmonella typhimurium harboring CCL22 miRNA on atopic dermatitis-like skin in mice","volume":"43","author":"Yoon","year":"2011","journal-title":"Exp Mol Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib178","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1021\/acsbiomaterials.4c01649","article-title":"Hydrogels treat atopic dermatitis by transporting marine-derived miR-100-5p-abundant extracellular vesicles","volume":"10","author":"Wu","year":"2024","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.apsb.2025.09.008_bib179","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/cei.12624","article-title":"MicroRNA-155 may be involved in the pathogenesis of atopic dermatitis by modulating the differentiation and function of T helper type 17 (Th17) cells","volume":"181","author":"Ma","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib180","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1038\/s41419-019-2124-x","article-title":"MicroRNA-155-5p is a key regulator of allergic inflammation, modulating the epithelial barrier by targeting PKI","volume":"10","author":"Wang","year":"2019","journal-title":"\u03b1. Cell Death Dis"},{"key":"10.1016\/j.apsb.2025.09.008_bib181","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1056\/NEJMoa1411776","article-title":"Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme","volume":"372","author":"Krug","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib182","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2015.09.022","article-title":"Efficacy of T-cell transcription factor-specific DNAzymes in murine skin inflammation models","volume":"137","author":"Purath","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib183","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202300374","article-title":"Therapeutic DNAzymes: from structure design to clinical applications","volume":"35","author":"Yan","year":"2023","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2025.09.008_bib184","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1111\/1523-1747.ep12607006","article-title":"Inhibition of interferon-gamma-induced intercellular adhesion molecule-1 expression on human keratinocytes by phosphorothioate antisense oligodeoxynucleotides is the consequence of antisense-specific and antisense-non-specific effects","volume":"104","author":"Hertl","year":"1995","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib185","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/oli.1.1998.8.319","article-title":"Specific inhibition of interleukin-10 production in murine macrophage-like cells by phosphorothioate antisense oligonucleotides","volume":"8","author":"Arima","year":"1998","journal-title":"Antisense Nucleic Acid Drug Dev"},{"key":"10.1016\/j.apsb.2025.09.008_bib186","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/cr.2008.282","article-title":"Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases","volume":"18","author":"Chen","year":"2008","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2025.09.008_bib187","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.09.008_bib188","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/15215","article-title":"New DNA enzyme targeting Egr-1 mRNA inhibits vascular smooth muscle proliferation and regrowth after injury","volume":"5","author":"Santiago","year":"1999","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib189","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1016\/j.biomaterials.2011.12.015","article-title":"Functional delivery of DNAzyme with iron oxide nanoparticles for hepatitis C virus gene knockdown","volume":"33","author":"Ryoo","year":"2012","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.09.008_bib190","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1038\/nm905","article-title":"Transcription factor Egr-1 supports FGF-dependent angiogenesis during neovascularization and tumor growth","volume":"9","author":"Fahmy","year":"2003","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib191","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1517\/14712598.2015.1025048","article-title":"DNA enzymes as potential therapeutics: towards clinical application of 10-23 DNAzymes","volume":"15","author":"Fokina","year":"2015","journal-title":"Expet Opin Biol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib192","unstructured":"Sterna Biologicals. sterna biologicals raises further EUR 10.0 million (approx. USD 11.9 million) in series A - 2nd closing private placement. Available from: https:\/\/www.sterna-biologicals.com\/company-news\/32sterna-biologicals-raises-further-eur-10-0-million-approx-usd-119-million-in-series-a-2nd-closing-private-placement. (Accessed 7 January 2021)."},{"key":"10.1016\/j.apsb.2025.09.008_bib193","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2007.12.1175","article-title":"Effective prevention and therapy of experimental allergic asthma using a GATA-3-specific DNAzyme","volume":"121","author":"Sel","year":"2008","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.apsb.2025.09.008_bib194","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijpharm.2011.03.023","article-title":"Protective effect of drug delivery systems against the enzymatic degradation of dermally applied DNAzyme","volume":"410","author":"Schmidts","year":"2011","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.09.008_bib195","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ijpharm.2010.07.037","article-title":"Development of multiple W\/O\/W emulsions as dermal carrier system for oligonucleotides: effect of additives on emulsion stability","volume":"398","author":"Schmidts","year":"2010","journal-title":"Int J Pharm"},{"key":"10.1016\/j.apsb.2025.09.008_bib196","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/nat.2017.0709","article-title":"Receptor-mediated uptake of phosphorothioate antisense oligonucleotides in different cell types of the liver","volume":"28","author":"Miller","year":"2018","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.apsb.2025.09.008_bib197","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1089\/nat.2017.0716","article-title":"Current challenges in delivery and cytosolic translocation of therapeutic RNAs","volume":"28","author":"Johannes","year":"2018","journal-title":"Nucleic Acid Therapeut"},{"key":"10.1016\/j.apsb.2025.09.008_bib198","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/cmdc.201000156","article-title":"Off-target effects related to the phosphorothioate modification of nucleic acids","volume":"5","author":"Winkler","year":"2010","journal-title":"ChemMedChem"},{"key":"10.1016\/j.apsb.2025.09.008_bib199","doi-asserted-by":"crossref","first-page":"2853","DOI":"10.1093\/nar\/gkaa126","article-title":"Comparison of the efficacy of MOE and PMO modifications of systemic antisense oligonucleotides in a severe SMA mouse model","volume":"48","author":"Sheng","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2025.09.008_bib200","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41467-018-02989-4","article-title":"Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity","volume":"9","author":"Janas","year":"2018","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.008_bib201","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1600-0625.2008.00786.x","article-title":"The skin: an indispensable barrier","volume":"17","author":"Proksch","year":"2008","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib202","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jconrel.2004.05.006","article-title":"Surfactant-enhanced transdermal delivery by electroporation","volume":"98","author":"Murthy","year":"2004","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.09.008_bib203","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/10611869808995877","article-title":"Antisense technology: selection and delivery of optimally acting antisense oligonucleotides","volume":"5","author":"Akhtar","year":"1998","journal-title":"J Drug Target"},{"key":"10.1016\/j.apsb.2025.09.008_bib204","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1016\/0024-3205(91)90480-Y","article-title":"Stability of antisense DNA oligodeoxynucleotide analogs in cellular extracts and sera","volume":"49","author":"Akhtar","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib205","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","article-title":"Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics","volume":"352","author":"Ramasamy","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.09.008_bib206","doi-asserted-by":"crossref","first-page":"7598","DOI":"10.1021\/la204913t","article-title":"Surface functionalization of silica nanoparticles supports colloidal stability in physiological media and facilitates internalization in cells","volume":"28","author":"Graf","year":"2012","journal-title":"Langmuir"},{"key":"10.1016\/j.apsb.2025.09.008_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/S0163-7258(01)00133-4","article-title":"Antisense oligonucleotides in cutaneous therapy","volume":"90","author":"Wraight","year":"2001","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib208","article-title":"Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res","volume":"32","author":"Minakuchi","year":"2004"},{"key":"10.1016\/j.apsb.2025.09.008_bib209","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jconrel.2022.05.032","article-title":"Laser-assisted nanocarrier delivery to achieve cutaneous siRNA targeting for attenuating psoriasiform dermatitis","volume":"347","author":"Lee","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.09.008_bib210","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0042655","article-title":"Efficacy of a novel class of RNA interference therapeutic agents","volume":"7","author":"Hamasaki","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2025.09.008_bib211","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103691","article-title":"Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm","volume":"74","author":"Grabowska-Pyrzewicz","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2025.09.008_bib212","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0167-4781(99)00140-2","article-title":"A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides","volume":"1489","author":"Levin","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.apsb.2025.09.008_bib213","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1177\/019262339902700103","article-title":"Synthetic oligonucleotides: the development of antisense therapeutics","volume":"27","author":"Monteith","year":"1999","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.apsb.2025.09.008_bib214","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1177\/019262339902700117","article-title":"Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1","volume":"27","author":"Henry","year":"1999","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.apsb.2025.09.008_bib215","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1089\/10430340050207984","article-title":"Comprehensive analysis of the acute toxicities induced by systemic administration of cationic lipid:plasmid DNA complexes in mice","volume":"11","author":"Tousignant","year":"2000","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib216","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1089\/104303401300057405","article-title":"Contribution of plasmid DNA to hepatotoxicity after systemic administration of lipoplexes","volume":"12","author":"Loisel","year":"2001","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib217","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1016\/j.ymthe.2023.08.016","article-title":"MicroRNA137-loaded lipid nanoparticles regulate synaptic proteins in the prefrontal cortex","volume":"31","author":"Palumbo","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib218","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1056\/NEJMc1912350","article-title":"Volanesorsen, familial chylomicronemia syndrome, and thrombocytopenia","volume":"381","author":"Khetarpal","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib219","doi-asserted-by":"crossref","first-page":"11449","DOI":"10.1073\/pnas.1411393111","article-title":"Correlating animal and human phase Ia\/Ib clinical data with CALAA-01, a targeted, polymer-based nanoparticle containing siRNA","volume":"111","author":"Zuckerman","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.09.008_bib220","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.addr.2003.08.005","article-title":"Atelocollagen for protein and gene delivery","volume":"55","author":"Sano","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.09.008_bib221","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.apsb.2025.09.008_bib222","doi-asserted-by":"crossref","first-page":"2388","DOI":"10.1016\/j.biomaterials.2010.11.081","article-title":"Polymer-related off-target effects in non-viral siRNA delivery","volume":"32","author":"Merkel","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.apsb.2025.09.008_bib223","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nbt831","article-title":"Expression profiling reveals off-target gene regulation by RNAi","volume":"21","author":"Jackson","year":"2003","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib224","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1038\/nature04791","article-title":"Fatality in mice due to oversaturation of cellular microRNA\/short hairpin RNA pathways","volume":"441","author":"Grimm","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.09.008_bib225","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","article-title":"Strategies, design, and chemistry in siRNA delivery systems","volume":"144","author":"Dong","year":"2019","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.09.008_bib226","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1021\/acs.bioconjchem.3c00393","article-title":"Diligent design enables antibody-ASO conjugates with optimal pharmacokinetic properties","volume":"34","author":"Sela","year":"2023","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.apsb.2025.09.008_bib227","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat Nanotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib228","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1038\/s41592-024-02487-0","article-title":"Accurate RNA 3D structure prediction using a language model-based deep learning approach","volume":"21","author":"Shen","year":"2024","journal-title":"Nat Methods"},{"key":"10.1016\/j.apsb.2025.09.008_bib229","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nsmb.2943","article-title":"Toll-like receptor 8 senses degradation products of single-stranded RNA","volume":"22","author":"Tanji","year":"2015","journal-title":"Nat Struct Mol Biol"},{"key":"10.1016\/j.apsb.2025.09.008_bib230","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nature06765","article-title":"Sequence- and target-independent angiogenesis suppression by siRNA via TLR3","volume":"452","author":"Kleinman","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2025.09.008_bib231","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.09.008_bib232","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.09.008_bib233","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1128\/MMBR.00027-06","article-title":"Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action","volume":"70","author":"Garc\u00eda","year":"2006","journal-title":"Microbiol Mol Biol Rev"},{"key":"10.1016\/j.apsb.2025.09.008_bib234","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1126\/science.1132505","article-title":"5\u2032-Triphosphate RNA is the ligand for RIG-I","volume":"314","author":"Hornung","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.apsb.2025.09.008_bib235","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd4685","article-title":"Clinical experiences with systemically administered siRNA-based therapeutics in cancer","volume":"14","author":"Zuckerman","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2025.09.008_bib236","doi-asserted-by":"crossref","first-page":"9742","DOI":"10.1073\/pnas.171251798","article-title":"Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems","volume":"98","author":"Caplen","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.09.008_bib237","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt1051","article-title":"Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy","volume":"23","author":"Kim","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib238","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nbt1206","article-title":"Stable expression of shRNAs in human CD34+ progenitor cells can avoid induction of interferon responses to siRNAs","volume":"24","author":"Robbins","year":"2006","journal-title":"in vitro. Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib239","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","article-title":"Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA","volume":"23","author":"Judge","year":"2005","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib240","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.omtn.2017.04.007","article-title":"Sustained inhibition of HBV replication in vivo after systemic injection of AAVs encoding artificial antiviral primary microRNAs","volume":"7","author":"Maepa","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2025.09.008_bib241","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tem.2014.06.008","article-title":"Mitochondrial DNA damage and atherosclerosis","volume":"25","author":"Yu","year":"2014","journal-title":"Trends Endocrinol Metabol"},{"key":"10.1016\/j.apsb.2025.09.008_bib242","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1038\/sj.mt.6300240","article-title":"2\u2032-O-Methyl-modified RNAs act as TLR7 antagonists","volume":"15","author":"Robbins","year":"2007","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib243","series-title":"Poly(ethylene glycol). chemistry and biological applications","first-page":"1","article-title":"Introduction to chemistry and biological applications of poly(ethylene glycol)","author":"Zalipsky","year":"1997"},{"key":"10.1016\/j.apsb.2025.09.008_bib244","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1038\/ki.1995.205","article-title":"Transport of phosphorothioate oligonucleotides in kidney: implications for molecular therapy","volume":"47","author":"Rappaport","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.apsb.2025.09.008_bib245","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/ard.1991.1.153","article-title":"The clearance and degradation of oligodeoxynucleotides following intravenous injection into rabbits","volume":"1","author":"Goodchild","year":"1991","journal-title":"Antisense Res Dev"},{"key":"10.1016\/j.apsb.2025.09.008_bib246","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0022-3565(25)38714-8","article-title":"Pharmacokinetics of a 14C-labeled phosphorothioate oligonucleotide, ISIS 2105, after intradermal administration to rats","volume":"269","author":"Cossum","year":"1994","journal-title":"J Pharmacol Exp Therapeut"},{"key":"10.1016\/j.apsb.2025.09.008_bib247","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/bdd.2510130308","article-title":"Organ distribution and stability of phosphorothioated oligodeoxyribonucleotides in mice","volume":"13","author":"Goodarzi","year":"1992","journal-title":"Biopharm Drug Dispos"},{"key":"10.1016\/j.apsb.2025.09.008_bib248","doi-asserted-by":"crossref","first-page":"7595","DOI":"10.1073\/pnas.88.17.7595","article-title":"Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice","volume":"88","author":"Agrawal","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2025.09.008_bib249","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1089\/ard.1994.4.99","article-title":"In vivo toxicological effects of rel A antisense phosphorothioates in CD-1 mice","volume":"4","author":"Sarmiento","year":"1994","journal-title":"Antisense Res Dev"},{"key":"10.1016\/j.apsb.2025.09.008_bib250","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-12-0429","article-title":"First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement","volume":"3","author":"Tabernero","year":"2013","journal-title":"Cancer Discov"},{"key":"10.1016\/j.apsb.2025.09.008_bib251","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1161\/ATVBAHA.111.237529","article-title":"ARC15105 is a potent antagonist of von Willebrand factor mediated platelet activation and adhesion","volume":"32","author":"Siller-Matula","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.apsb.2025.09.008_bib252","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.omtn.2017.10.004","article-title":"An albumin-oligonucleotide assembly for potential combinatorial drug delivery and half-life extension applications","volume":"9","author":"Kuhlmann","year":"2017","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2025.09.008_bib253","unstructured":"Simulations Plus Investor Relations. Simulations plus releases GastroPlus\u00ae X, the next generation PBPK\/PBBM modeling & simulation software. Available from: https:\/\/www.businesswire.com\/news\/home\/20240515037814\/en\/Simulations-Plus-Releases-GastroPlus-X-The-Next-Generation-PBPKPBBM-Modeling-Simulation-Software. (Accessed 15 May 2024)."},{"key":"10.1016\/j.apsb.2025.09.008_bib254","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2023.02.021","article-title":"Investigations into the FLG null phenotype: showcasing the methodology for CRISPR\/Cas9 editing of human keratinocytes","volume":"143","author":"Smits","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib255","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/nar\/gkv1206","article-title":"Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides","volume":"44","author":"Lennox","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.apsb.2025.09.008_bib256","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1111\/jcmm.17473","article-title":"circRNA: regulatory factors and potential therapeutic targets in inflammatory dermatoses","volume":"26","author":"Liu","year":"2022","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib257","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.3390\/ijms19103263","article-title":"Integrative analysis of lncRNAs, miRNAs, and mRNA-associated ceRNA network in an atopic dermatitis recurrence model","volume":"19","author":"Wang","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2025.09.008_bib258","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1016\/j.ymthe.2020.04.006","article-title":"Engineered circular RNA sponges act as miRNA inhibitors to attenuate pressure overload-induced cardiac hypertrophy","volume":"28","author":"Lavenniah","year":"2020","journal-title":"Mol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib259","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1021\/acs.molpharmaceut.0c00997","article-title":"Development of a liquid crystal formulation that can penetrate the stratum corneum for intradermal delivery of small interfering RNA","volume":"18","author":"Kawai","year":"2021","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2025.09.008_bib260","unstructured":"Sarepta Therapeutics. Sarepta therapeutics announces that FDA has lifted its clinical hold on SRP-5051 for the treatment of duchenne muscular dystrophy. Available from: https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-announces-fda-has-lifted-its-clinical-hold. (Accessed 9 June 2022)."},{"key":"10.1016\/j.apsb.2025.09.008_bib261","doi-asserted-by":"crossref","DOI":"10.1016\/j.jphotochemrev.2021.100420","article-title":"NIR light-responsive nanocarriers for controlled release","volume":"47","author":"Tang","year":"2021","journal-title":"J Photochem Photobiol, C"},{"key":"10.1016\/j.apsb.2025.09.008_bib262","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.addr.2020.09.001","article-title":"Advances on erythrocyte-mimicking nanovehicles to overcome barriers in biological microenvironments","volume":"170","author":"Castro","year":"2021","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2025.09.008_bib263","doi-asserted-by":"crossref","first-page":"440","DOI":"10.3390\/gels10070440","article-title":"Stimulus-responsive hydrogels for targeted cancer therapy","volume":"10","author":"Solanki","year":"2024","journal-title":"Gels"},{"key":"10.1016\/j.apsb.2025.09.008_bib264","article-title":"Stimulus-responsive hydrogels as drug delivery systems for inflammation targeted therapy","volume":"11","author":"Yu","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2025.09.008_bib265","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1016\/j.apsb.2025.02.038","article-title":"Microneedle delivery platform integrated with staphylococcus epidermidis-derived extracellular vesicles-based nanoantibiotics for efficient bacterial infection atopic dermatitis treatment","volume":"15","author":"Zhou","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2025.09.008_bib266","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/s41467-024-46215-w","article-title":"Long-term monitoring of ultratrace nucleic acids using tetrahedral nanostructure-based NgAgo on wearable microneedles","volume":"15","author":"Yang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.008_bib267","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jconrel.2024.11.020","article-title":"Toward precision medicine: End-to-end design and construction of integrated microneedle-based theranostic systems","volume":"377","author":"Qin","year":"2025","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2025.09.008_bib268","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/nbt.4136","article-title":"Reversal of siRNA-mediated gene silencing","volume":"36","author":"Zlatev","year":"2018","journal-title":"in vivo. Nat Biotechnol"},{"key":"10.1016\/j.apsb.2025.09.008_bib269","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.ccell.2022.08.006","article-title":"Detection and localization of early- and late-stage cancers using platelet RNA","volume":"40","author":"In 't Veld","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2025.09.008_bib270","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1038\/s41551-023-01081-7","article-title":"Profiling of repetitive RNA sequences in the blood plasma of patients with cancer","volume":"7","author":"Reggiardo","year":"2023","journal-title":"Nat Biomed Eng"},{"key":"10.1016\/j.apsb.2025.09.008_bib271","unstructured":"GlobalData Healthcare. Pay-for-performance deals for pharmaceuticals continue to gain momentum in the US. Available from: https:\/\/www.pharmaceutical-technology.com\/comment\/commentpay-for-performance-deals-for-pharmaceuticals-continue-to-gain-momentum-in-the-us-5755103\/. (Accessed 3 March 2017)."},{"key":"10.1016\/j.apsb.2025.09.008_bib272","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1038\/s41467-021-24598-4","article-title":"Fully automated fast-flow synthesis of antisense phosphorodiamidate morpholino oligomers","volume":"12","author":"Li","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2025.09.008_bib273","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1111\/all.16183","article-title":"Integrating multi-omics approaches in deciphering atopic dermatitis pathogenesis and future therapeutic directions","volume":"79","author":"Nakajima","year":"2024","journal-title":"Allergy"},{"key":"10.1016\/j.apsb.2025.09.008_bib274","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1016\/j.jid.2024.04.032","article-title":"Targeting the complexity of in vitro skin models: a review of cutting-edge developments","volume":"144","author":"Qu\u00edlez","year":"2024","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.apsb.2025.09.008_bib275","doi-asserted-by":"crossref","first-page":"19622","DOI":"10.1021\/jacs.0c08691","article-title":"Do aptamers always bind? The need for a multifaceted analytical approach when demonstrating binding affinity between aptamer and low molecular weight compounds","volume":"142","author":"Bottari","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.apsb.2025.09.008_bib276","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2021.116480","article-title":"Critical evaluation of aptamer binding for biosensor designs","volume":"146","author":"Zhao","year":"2022","journal-title":"Trends Analyt Chem"},{"key":"10.1016\/j.apsb.2025.09.008_bib277","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107967","article-title":"Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination","volume":"230","author":"Yu","year":"2022","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.apsb.2025.09.008_bib278","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2025.09.008_bib279","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nature24049","article-title":"RNA targeting with CRISPR-Cas13a","volume":"550","author":"Abudayyeh","year":"2017","journal-title":"Nature"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006057?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383525006057?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T22:58:35Z","timestamp":1762815515000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383525006057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":279,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2211383525006057"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2025.09.008","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antisense molecules: A promising new therapy for atopic dermatitis","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2025.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}